Skip to content
[P]pubcas
Independent chemical reference Compare
Chemical substance record

Pomalidomide

19171-19-8C13H11N3O4273.248 g/mol

An aromatic amine that is thalidomide substituted at position 4 on the isoindole ring system by an amino group. Used for the treatment of multiple myeloma in patients who failed to respond to previous therapies. — ChEBI

Safety references

Safety documents & references

Supplier matching matters

Find the safety document for your specific supplier, product number and grade.

Find a product-specific SDS

Safety guides and government classification records are not a manufacturer’s SDS. Match supplier, product number, concentration, physical form, region and revision before using a document.

Identity & molecular properties

Source-linked values
CAS number19171-19-8ChEBI ↗
Molecular formulaC13H11N3O4ChEBI ↗
Molar mass273.248 g/molChEBI ↗
Monoisotopic mass273.07496 DaChEBI ↗
Formal charge0ChEBI ↗
ChEBI identifierCHEBI:72690ChEBI ↗

Cross-source molecular data

PubChem
Molar mass273.24 g/molPubChem ↗
Exact mass273.07495584 DaPubChem ↗
Computed XLogP0.2PubChem ↗
Topological polar surface area (Ų)110PubChem ↗
H-bond donors2PubChem ↗
H-bond acceptors5PubChem ↗
Rotatable bonds1PubChem ↗

PubChem computed values are shown separately from the ChEBI record. An exact InChIKey match was used to connect the records. Molecular descriptors do not describe a supplied product’s purity, particle size or performance.

Names & structural identifiers

Copy any identifier
pomalidomide
4-amino-2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione
UVSMNLNDYGZFPF-UHFFFAOYSA-N
Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O
InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)

Names & synonyms

4-amino-2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dionePomalyst

Names are supplied by ChEBI. Trade names and related synonyms may describe a broader product context.

Classification & relationships

ChEBI ontology

Roles recorded in ChEBI

antifibrotic agentantineoplastic agentangiogenesis inhibitorimmunomodulatoranti-anaemic agent

Database role annotations describe reported biological or chemical roles; they are not product approvals or recommendations for use.

Mass ↔ amount of substance

Calculated from sourced mass
Equivalent amount
0.00365968 mol

Uses 273.248 g/mol from ChEBI. Assumes the substance described by this record; no purity or concentration correction is applied.

Elemental composition

Theoretical mass fractions
C
Carbon · 13 atoms
57.14%
O
Oxygen · 4 atoms
23.42%
N
Nitrogen · 3 atoms
15.38%
H
Hydrogen · 11 atoms
4.06%

Calculated theoretical mass fractions from the reported formula and PubChem periodic-table atomic masses. These are not assay or purity results.

Research & patent references

Selected source associations
Long-term outcome of pomalidomide therapy in myelofibrosis. ↗American journal of hematology · 2012 Jan · PMID 22081489
Management of myeloproliferative neoplasms: from academic guidelines to clinical practice. ↗Current hematologic malignancy reports · 2012 Mar · PMID 22278747
US2007004920 · Patent reference ↗Patent cross-reference supplied by ChEBI. Association alone does not establish claim scope.
US2007048327 · Patent reference ↗Patent cross-reference supplied by ChEBI. Association alone does not establish claim scope.
US2007155791 · Patent reference ↗Patent cross-reference supplied by ChEBI. Association alone does not establish claim scope.

Sources & record history

Checked 27 Sep 2026
EMBL-EBI ChEBI · CHEBI:72690

Release 255, 9 September 2026. ChEBI three-star (manually annotated) source entry. View original record ↗ · CC BY 4.0

NCBI PubChem · CID 134780 · retrieved 2026-09-27

PubCAS formats source data, connects references and computes explicitly labelled conversions. CAS cross-references are supplied by ChEBI; they do not constitute CAS verification or endorsement.